Human hybridomas derived from CDS+ B lymphocytes of patients with chronic lymphocytic leukemia (B‐CLL) produce multi‐specific natural IgM (kappa) antibodies

• Published in: Clinical and experimental immunology Vol. 83; no. 3; pp. 413 - 417
• Main Authors: JAHN, S., SCHWAB, J., HANSEN, A., HEIDER, H., SCHROEDER, C., LUKOWSKY, A., ACHTMAN, M., MATTHES, H., KIESSIG, S. T., VOLK, H. D., KRUEGER, D. H., BAEHR, R.
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 28.06.2008
• Subjects: CD5+ B cells; chronic lymphocytic leukemia; human monoclonal antibodies; natural antibodies
• ISSN: 0009-9104; 1365-2249
• DOI: 10.1111/j.1365-2249.1991.tb05653.x

SUMMARY Great numbers of CD5+ B lymphocytes were detected in the peripheral blood of patients with B‐CLL. To study the antibody repertoire of this immune cell subpopulation on a monoclonal level, we fused the lymphocytes derived from five different donors to a highly efficient HAT‐sensitive heteromye‐loma line (CB‐F7). A fusion frequency of up to 10‐5 allowed us to analyse hundreds of initial hybridoma lines per fusion. In all culture supernatants in three out of five fusions IgM lambda antibodies were detected, in two experiments only IgM kappa was measured, suggesting monoclonality of the primary hybridoma cell lines. The later fusions resulted in hybridomas producing multi‐specific antibodies against both an autoantigen and an infectious agent: (i) dsDNA/influenza virus haemagglutinin; (ii) dsDNA/class V outer membrane protein type C from Neisseria meningitidis. However, no antibodies of the described specificity were detected in blood sera of patients, indicating a ‘switch‐on’ of the immunoglobulin secretion capacity of malignant B cells during fusion to a myeloma partner. We discuss the results as further evidence for the natural multi‐reactive antibody repertoire of CD5+ B cells.